CYDY CYTODYN INC
- 0.134550
- +0.004750+3.66%
CYTODYN INC News
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
Express News | Cytodyn Engages Leading Cro for Phase II Inflammation Trial
CYTODYN INC | 10-K: FY2024 Annual Report
Express News | Cytodyn Inc: Intends to Proceed With a Submission of Its Final Study Protocol to FDA
Express News | Cytodyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients With Relapsed/Refractory Microsatellite Stable Colorectal Cancer
Express News | Cytodyn Inc - Terms of Settlement Provide an Immediate Influx of Non-Dilutive Cash and Eliminates $14 Mln of Accounts Payable
Express News | Cytodyn Inc - Amarex to Pay Cytodyn $12 Million
Express News | Cytodyn Announces Settlement With Amarex Clinical Research LLC
FDA Lifts Clinical Hold on CytoDyn Drug, Stock Rallies 22%
Express News | CytoDyn Announces Submission Of Clinical Protocol To FDA And Initiation Of Pre-Clinical Study In Glioblastoma
Express News | CytoDyn Appoints Jacob Lalezari As CEO, Effective Jan. 26, 2024; Mitchell Cohen Appointed Interim CFO, Effective Feb. 1, 2024
CytoDyn Appoints Lalezari as Its Interim CEO
CytoDyn President Cyrus Arman Takes Medical Leave
CytoDyn to Host Conference Call
CytoDyn to Hold Webcast to Provide a Company Update
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
CytoDyn Shares Drop After Former CEO Charged With Securities Fraud -- WSJ
Short Interest in CytoDyn Inc. (OTCMKTS:CYDY) Declines By 5.9%
CytoDyn Voluntarily Withdrawing BLA for HIV Treatment Leronlimab
CytoDyn Announces Appointment of Additional Directors With Industry Experience
Analysis
Price Target
No Data
